<\/p>\n
Dilvas<\/strong> is a 2.5 \/ 5 \/ 10 mg enalapril tablet<\/strong> from a WHO-GMP certified manufacturer — an angiotensin-converting enzyme (ACE) inhibitor<\/strong>. ACE inhibitors are first-line antihypertensive therapy<\/strong> in most international guidelines (NICE, AHA\/ACC, ESC\/ESH), particularly for patients under 55 and for diabetics, heart-failure patients, post-MI patients, and those with proteinuric kidney disease. Enalapril is a prodrug<\/strong> converted in the liver to enalaprilat (the active ACE inhibitor) with effective half-life 11 hours (enalaprilat) — usually once-daily; occasionally divided twice daily. Typical hypertension dose: start 5 mg once daily (2.5 mg if elderly, renal impaired, volume depleted, or on a diuretic), titrate to 10-20 mg once daily<\/strong>. Main side effect: dry persistent cough<\/strong> (up to 20% of users, class effect; if intolerable, switch to an ARB such as losartan<\/a> or telmisartan<\/a>). Other class effects: hyperkalaemia, first-dose hypotension, reversible rise in creatinine at start. Absolutely contraindicated in pregnancy<\/strong> (all trimesters — causes fetal renal agenesis, oligohydramnios, pulmonary hypoplasia, skull defects), bilateral renal artery stenosis, and history of ACE-inhibitor-induced angioedema.<\/p>\n<\/div>\n \ud83d\udce6 Every order is covered by our Reshipment Assurance Policy<\/strong><\/a> \u2014 if your parcel does not arrive within 20 business days, we reship it.<\/p>\n Our generic medications are sourced from WHO-GMP certified manufacturers and shipped worldwide in discreet, plain packaging \u2014 no medication name on the parcel exterior. Card payments are routed through a regulated processor (statement descriptors include a regulated card-payment processor \u2014 never “MedsBase” or any medication name). Crypto and SEPA bank transfer are also accepted. Every order is backed by our Reshipment Assurance Policy.<\/p>\n Dilvas is an oral 2.5 \/ 5 \/ 10 mg enalapril tablet from a WHO-GMP certified manufacturer, supplied in 30-90 tablets. Introduced 1984 as Vasotec \/ Renitec<\/strong> (MSD) — the second ACE inhibitor ever marketed after captopril, and the first oral once-daily agent in the class.<\/p>\n Enalapril is a prodrug<\/strong> converted in the liver to enalaprilat (the active ACE inhibitor), with effective half-life 11 hours (enalaprilat) — usually once-daily; occasionally divided twice daily.<\/p>\n ACE inhibitors block the angiotensin-converting enzyme<\/strong>, which catalyses the conversion of inactive angiotensin I to active angiotensin II. Angiotensin II is a potent vasoconstrictor and the primary stimulus for adrenal aldosterone release. Blocking its formation produces:<\/p>\n Pivotal trial evidence:<\/strong> CONSENSUS trial (1987) — enalapril reduced mortality by 40% in NYHA class IV heart failure. SOLVD trial — mortality and hospitalisation reduction in HF-REF. These were the two first large-scale demonstrations that ACE inhibitors save lives in heart failure, establishing the class as cornerstone therapy.<\/p>\n Hypertension:<\/strong><\/p>\n Heart failure with reduced ejection fraction (HF-REF):<\/strong> Start 2.5 mg twice daily; titrate to 10-20 mg twice daily (HF-REF target)<\/p>\n Post-myocardial infarction:<\/strong> 2.5-20 mg\/day<\/p>\n First-dose precautions:<\/strong> first-dose hypotension is most likely in patients on high-dose diuretics, in dehydrated patients, in heart failure, and in elderly patients. Take the first dose at bedtime; monitor BP; hold diuretics for 24-48 hours before starting if possible.<\/p>\n Monitoring:<\/strong><\/p>\n Discontinuation:<\/strong> tapering is not strictly required for ACE inhibitors (unlike beta-blockers), but abrupt discontinuation causes BP rebound within days. If stopping, taper over 1-2 weeks and monitor BP.<\/p>\n Common (>5%):<\/strong><\/p>\n Uncommon but important:<\/strong><\/p>\n Breastfeeding:<\/strong> enalapril and captopril are considered compatible (small amounts in breast milk); data for enalapril is limited — avoid in the first weeks after delivery of a premature infant; generally acceptable thereafter.<\/p>\nWhy order from MedsBase<\/h3>\n
What Is Dilvas?<\/h2>\n
How Enalapril Lowers Blood Pressure<\/h2>\n
\n
Approved and Evidence-Based Uses<\/h2>\n
\n
Dilvas Dosage<\/h2>\n
\n
\n
Side Effects<\/h2>\n
\n
\n
Contraindications<\/h2>\n
\n
Drug Interactions<\/h2>\n
\n
ACE Inhibitor Class at a Glance<\/h2>\n